Amifostine enhances recovery and expansion of peripheral FAS/CD95+ T- and NK-cell subpopulations during radiotherapy of patients with head-neck cancer

References

• Andrews G A. Radiation accidents and their management. Radiation Research Supply 1967; 7: 390–397
   PubMedGoogle Scholar
• Badoual C, Hans S, Rodriguez J, Peyrard S, Klein C, Agueznay Nel H, Mosseri V, Laccourreye O, Bruneval P, Fridman W H, Brasnu D F, Tartour E. Prognostic value of tumor-infiltrating CD4+ T-cell subpopulations in head and neck cancers. Clinical Cancer Research 2006; 12: 465–472
   PubMed Web of Science ®Google Scholar
• Chakraborty M, Abrams S I, Coleman C N, Camphausen K, Schlom J, Hodge J W. External beam radiation of tumors alters phenotype of tumor cells to renderthem susceptible to vaccine-mediated T-cell killing. Cancer Research 2004; 64: 4328–4337
   PubMed Web of Science ®Google Scholar
• Daniel V, Weimer R, Schimpf K, Opelz G. Autoantibodies against CD4+ and CD8+ T- lymphocytes in HIV-infected hemophilia patients. Vox Sanguinis 1989; 57: 172–176
   PubMed Web of Science ®Google Scholar
• David H, Martin C. Practical longitudinal data analysis. Texts in Statistical Science Series. Chapman & Hall, London 1999
   Google Scholar
• Garnett C T, Palena C, Chakraborty M, Chakarborty M, Tsang K Y, Schlom J, Hodge J W. Sublethal irradiation of human tumor cells modulates phenotype resulting in enhanced killing by cytotoxic T lymphocytes. Cancer Research 2005; 65: 374
   Google Scholar
• Gray W C, Chrétien P B, Suter C M, Revie D R, Tomazic V T, Blanchard C L, Aygun C, Amornmarn R, Ordonez J V. Effect of radiation therapy on T-lymphocyte subpopulations in patients with head and neck cancer. Otolaryngology-head and Neck Surgery 1985; 93: 650–659
   PubMed Web of Science ®Google Scholar
• Hagen J H, Hanahan D. Tumor cells utilize multiple pathways to down modulate apoptosis. Lessons from a mouse model of islet cell carcinogenesis. Annals of the New York Academy of Sciences 1999; 887: 150–163
   PubMedGoogle Scholar
• Houston A, O'Connell J. The Fas signalling pathway and its role in the pathogenesis of cancer. Current Opinion in Pharmacology 2004; 4: 321–326
   PubMed Web of Science ®Google Scholar
• Ioachim H L, Decuseara R, Giancotti F, Dorsett B H. FAS and FAS-L expression by tumor cells and lymphocytes in breast carcinomas and their lymphnode metastases. Pathology Research and Practice 2005; 200: 743–751
   PubMedGoogle Scholar
• Ingey F H, Krammer P H. Death and anti-death: Tumor resistance to apoptosis. Nature Reviews Cancer 2002; 2: 277–288
   PubMedGoogle Scholar
• Itoh N, Yonehara S, Ishii A, Yonehara M, Mizushima S, Sameshima M, Hase A, Seto Y, Nagata S. The polypeptide encoded by the CDNA for human cell surface antigen Fas can mediate apoptosis. Cell 1991; 66: 233–243
   PubMed Web of Science ®Google Scholar
• Kim R, Emi M, Tanabe K, Uchida Y, Toge T. The role of Fas ligand and transforming growth factor beta in tumor progression: Molecular mechanisms of immune privilege via Fas-mediated apoptosis and potential targets for cancer therapy. Cancer 2004; 100: 2281–2291
   PubMed Web of Science ®Google Scholar
• Korsmeyer S J. Bcl-2 initiates a new category of oncogenes: Regulators of cell death. Blood 1992; 81: 151–157
   Google Scholar
• Krammer P H, Galle P R, Moller P, Debatin K M. CD95 (APO-1/FAS)-mediated apoptosis in normal and malignant liver, colon and hematopoietic cells. Advanced Cancer Research 1998; 75: 251–273
   PubMed Web of Science ®Google Scholar
• Koukourakis M I, Kourousis C, Kamilaki M, Koukouraki S, Giatromanolaki A, Kakolyris S, Kotsakis A, Androulakis N, Bahlitzanakis N, Georgoulias V. Weekly docetaxel and concomitant boost radiotherapy for non-small cell lung cancer. A phase I/II dose escalation trial. European Journal of Cancer 1998; 34: 838–844
   PubMed Web of Science ®Google Scholar
• Koukourakis M I, Ktenidou-Kartali S, Bourikas G, Kartalis G, Tsatalas C. Amifostine protects lymphocytes during radiotherapy and stimulates expansion of the CD95/FAS and CD31 expressing T-cells in breast cancer patients. Cancer Immunology and Immunotherapy 2003; 52: 127–131
   PubMedGoogle Scholar
• Kuss I, Hathaway B, Ferris R L, Gooding W, Whiteside T L. Decreased absolute counts of T lymphocyte subsets and their relation to disease in squamous cell carcinoma of the head and neck. Clinical Cancer Research 2004; 10: 3755–3762
   PubMed Web of Science ®Google Scholar
• Littell R C, Milliken G A, Stroup W W, Wolfinger R D. SAS system for mixed models. SAS institute. 1996
   Google Scholar
• Molling J W, Langius J A, Langendijk J A, Leemans C R, Bontkes H J, van der Vliet H J, von Blomberg B M, Scheper R J, van den Eertwegh A J. Low levels of circulating invariant natural killer T cells predict poor clinical outcome in patients with head and neck squamous cell carcinoma. Journal of Clinical Oncology 2007; 25: 862–868
   PubMed Web of Science ®Google Scholar
• Murakami M, Sasaki T, Yamasaki S, Kuwahara K, Miyata H, Chayama K. Induction of apoptosis by ionizing radiation and CI-1033 in HuCCT-1 cells. Biochemical and Biophysical Research Communications 2004; 319: 114–119
   PubMedGoogle Scholar
• Murta E F, de Andrade J M, Falcao R P, Bighetti S. Lymphocyte subpopulation in patients with advanced breast cancer submitted to neoadjuvant chemotherapy. Tumori 2000; 86: 403–407
   PubMed Web of Science ®Google Scholar
• Nicolatou-Galitis O, Sotiropoulou-Lontou A, Velegraki A, Pissakas G, Kolitsi G, Kyprianou K, Kouloulias V, Papanikolaou I, Yiotakis I, Dardoufas K. Oral candidiasis in head and neck cancer patients receiving radiotherapy with amifostine cytoprotection. Oral Oncology 2003; 39: 397–401
   PubMed Web of Science ®Google Scholar
• Reckzeh B, Merte H, Pfluger K H, Pfab R, Wolf M, Havemann K. Severe lymphocytopenia and interstitial pneumonia in patients treated with paclitaxel and simultaneous radiotherapy for non-small-cell lung cancer. Journal of Clinical Oncology 1996; 14: 1071–1076
   PubMed Web of Science ®Google Scholar
• Rivoltini L, Carrabba M, Huber V, Castelli C, Novellino L, Dalerba P, Mortarini R, Arancia G, Anichini A, Fais S, Parmiani G. Immunity to cancer: Attack and escape in T lymphocyte-tumor cell interaction. Immunology 2002; 188: 97–113
   Google Scholar
• Santin A D, Hermonat P L, Ravaggi A, Bellone S, Roman J, Pecorelli S. Effects of concurrent cisplatinum administration during radiotherapy vs. radiotherapy alone on the immune function of patients with cancer of the uterine cervix. International Journal of Radiation Oncology Biology Physics 2000; 48: 997–1006
   PubMed Web of Science ®Google Scholar
• Scholz M, Cinatl J. Fas/FasL interaction: A novel immune therapy approach with immobilized biologicals. Medicinal Research Reviews 2005; 25: 331–342
   PubMed Web of Science ®Google Scholar
• Sheard M A. Ionizing radiation as a response-enhancing agent for CD95-mediated apoptosis. International Journal of Cancer 2001; 96: 213–220
   PubMed Web of Science ®Google Scholar
• Smyth M J, Wallace M E, Nutt S L, Yagita H, Godfrey D I, Hayakawa Y. Sequential activation of NKT cells and NK cells provides effective innate immunotherapy of cancer. The Journal of Experimental Medicine 2005; 201: 1973–1985
   PubMed Web of Science ®Google Scholar
• Somma P, Lo Muzio L, Mansueto G, Delfino M, Fabbrocini G, Mascolo M, Mignogna C, Di Benedetto M, Carinci F, De Lillo A, Pastore L, Serpico R, De Rosa G, Staibano S. Squamous cell carcinoma of the lower lip: FAS/FASL expression, lymphocyte subtypes and outcome. International Journal of Immunopathology and Pharmacology 2005; 18: 59–64
   PubMedGoogle Scholar
• Sprick M R, Weigand M A, Rieser E, Rauch C T, Juo P, Blenis J, Krammer P H, Walczak H. FADD/MORT 1 and caspase-8 are recruited to TRAIL receptors 1 and 2 and are essential for apoptosis mediated by TRAIL receptor 2. Immunity 2000; 12: 599–609
   PubMed Web of Science ®Google Scholar
• Suda T, Takahashi T, Golstein D, Nagata S. Molecular cloning and expression of the fas ligand a novel member of the tumor necrosis factor family. Cell 1993; 75: 1169–1178
   PubMed Web of Science ®Google Scholar
• Tarpley J L, Porvin C, Chretien P B. Prolonged depression of cellular immunity in cured laryngopharyngeal cancer patients treated with radiation therapy. Cancer 1975; 35: 638–644
   PubMed Web of Science ®Google Scholar
• Tisch M, Heimlich F, Daniel V, Opelz G Maier. Cellular Immune defect caused by post-surgical radiation therapy in patients with head and neck cancer. Otolaryngology-head and Neck Surgery 1998; 119: 412–417
   PubMedGoogle Scholar
• Uno M, Otsuki T, Yata K, Fujii T, Sakaguchi H, Akisada T, Hiratsuka J, Imajo Y, Harada T. Participation of Fas-mediated apoptotic pathway in KB, a human head and neck squamous cell carcinoma cell line, after irradiation. International Journal of Oncology 2002; 20: 617–622
   PubMed Web of Science ®Google Scholar
• Yamanaka R, Tanaka R, Yoshida S, Mori H, Takeda N, Satoh M. Effects of ACNU and cranial irradiation on the mouse immune system. Neurologia medico- Chirurgica (Tokyo) 1993; 33: 65–70
   PubMedGoogle Scholar
• Zar J H. Biostatistical analysis. Ecology 1996; 77(7)2266–2267
   Google Scholar